|
1
|
Field JK, Oudkerk M, Pedersen JH and Duffy
SW: Prospects for population screening and diagnosis of lung
cancer. Lancet. 382:732–741. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ozawa Y, Inui N, Naitoh T, et al: Phase II
study of combination chemotherapy with S-1 and weekly cisplatin in
patients with previously untreated advanced non-small cell lung
cancer. Lung Cancer. 63:68–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barr MP, Gray SG, Hoffmann AC, et al:
Generation and characterisation of cisplatin-resistant non-small
cell lung cancer cell lines displaying a stem-like signature. PloS
One. 8:e541932013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sève P and Dumontet C: Chemoresistance in
non-small cell lung cancer. Curr Med Chem Anticancer Agents.
5:73–88. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Almeida GM, Duarte TL, Farmer PB, Steward
WP and Jones GD: Multiple end-point analysis reveals cisplatin
damage tolerance to be a chemoresistance mechanism in a NSCLC
model: implications for predictive testing. Int J Cancer.
122:1810–1819. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McCabe MT, Brandes JC and Vertino PM:
Cancer DNA methylation: molecular mechanisms and clinical
implications. Clin Cancer Res. 15:3927–3937. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheung HH, Lee TL, Rennert OM and Chan WY:
DNA methylation of cancer genome. Birth Defects Res C Embryo Today.
87:335–350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fang JY, Yang L, Zhu HY, Chen YX, Lu J, Lu
R, Cheng ZH and Xiao SD: 5-Aza-2′-deoxycitydine induces
demethylation and up-regulates transcription of p16INK4a gene in
human gastric cancer cell lines. Chin Med J (Engl). 117:99–103.
2004.PubMed/NCBI
|
|
10
|
Chu LC, Eberhart CG, Grossman SA and
Herman JG: Epigenetic silencing of multiple genes in primary CNS
lymphoma. Int J Cancer. 119:2487–2491. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Karahoca M and Momparler RL:
Pharmacokinetic and pharmacodynamic analysis of
5-aza-2′-deoxycytidine (decitabine) in the design of its
dose-schedule for cancer therapy. Clin Epigenetics. 5:32013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mund C, Hackanson B, Stresemann C, Lübbert
M and Lyko F: Characterization of DNA demethylation effects induced
by 5-aza-2′-deoxycytidine in patients with myelodysplastic
syndrome. Cancer Res. 65:7086–7090. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Belinsky SA: Gene-promoter
hypermethylation as a biomarker in lung cancer. Nat Rev Cancer.
4:707–717. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Belinsky SA: Silencing of genes by
promoter hypermethylation: key event in rodent and human lung
cancer. Carcinogenesis. 26:1481–1487. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pfeifer GP and Rauch TA: DNA methylation
patterns in lung carcinomas. Semin Cancer Biol. 19:181–187. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fleischhacker M, Dietrich D, Liebenberg V,
Field JK and Schmidt B: The role of DNA methylation as biomarkers
in the clinical management of lung cancer. Expert Rev Respi Med.
7:363–383. 2013. View Article : Google Scholar
|
|
17
|
Charlet J, Schnekenburger M, Brown KW and
Diederich M: DNA demethylation increases sensitivity of
neuroblastoma cells to chemotherapeutic drugs. Biochem Pharmacol.
83:858–865. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shang D, Liu Y, Matsui Y, et al:
Demethylating agent 5-aza-2′-deoxycytidine enhances susceptibility
of bladder transitional cell carcinoma to cisplatin. Urology.
71:1220–1225. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han S, Sermba S, Abe T, Makino N, Furukawa
T, Fukushige S, Takahashi H, Sakurada A, Sato M, Shiiba K, et al:
Infrequent somatic mutations of the p73 gene in various human
cancers. Eur J Surg Oncol. 25:194–198. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoshikawa H, Nagashima M, Khan MA,
McMenamin MG, Hagiwara K and Harris CC: Mutational analysis of p73
and p53 in human cancer cell lines. Oncogene. 18:3415–3421. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maas AM, Bretz AC, Mack E and Stiewe T:
Targeting p73 in cancer. Cancer Lett. 332:229–236. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao Y, Fei C, Zhang X, et al: Methylation
of the p73 gene in patients with myelodysplastic syndromes:
correlations with apoptosis and prognosis. Tumour Biol. 34:165–172.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pei JH, Luo SQ, Zhong Y, Chen JH, Xiao HW
and Hu WX: The association between non-Hodgkin lymphoma and
methylation of p73. Tumour biol. 32:1133–1138. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu K, Zhan M and Zheng P: Loss of p73
expression in six non-small cell lung cancer cell lines is
associated with 5′CpG island methylation. Exp Mol Pathol. 84:59–63.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu K, Zhuang X and Mai Z: p73 expression
is associated with cellular chemosensitivity in human non-small
cell lung cancer cell lines. Oncol Lett. 5:583–587. 2013.PubMed/NCBI
|
|
26
|
Kim DH, Nelson HH, Wiencke JK, et al:
p16(INK4a) and histology-specific methylation of CpG islands by
exposure to tobacco smoke in non-small cell lung cancer. Cancer
Res. 61:3419–3424. 2001.PubMed/NCBI
|
|
27
|
Bearzatto A, Conte D, Frattini M, et al:
p16(INK4A) hypermethylation detected by fluorescent
methylation-specific PCR in plasmas from non-small cell lung
cancer. Clin Cancer Res. 8:3782–3787. 2002.PubMed/NCBI
|
|
28
|
Shin KC, Lee KH, Lee CH, Shin IH, Suh HS
and Jeon CH: MAGE A1-A6 RT-PCR and MAGE A3 and p16 methylation
analysis in induced sputum from patients with lung cancer and
non-malignant lung diseases. Oncol Rep. 27:911–916. 2012.PubMed/NCBI
|
|
29
|
Lou-Qian Z, Rong Y, Ming L, Xin Y, Feng J
and Lin X: The prognostic value of epigenetic silencing of p16 gene
in NSCLC patients: a systematic review and meta-analysis. PloS One.
8:e549702013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zinkel S, Gross A and Yang E: BCL2 family
in DNA damage and cell cycle control. Cell Death Differ.
13:1351–1359. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hervouet E, Vallette FM and Cartron PF:
Impact of the DNA methyltransferases expression on the methylation
status of apoptosis-associated genes in glioblastoma multiforme.
Cell Death Dis. 1:e82010. View Article : Google Scholar : PubMed/NCBI
|
